Israeli advanced digital microscopy and platform developer Scopio Labs has closed a $7 million financing round from investors including OurCrowd.
Scopio Labs, founded in 2015 by CEO Itai Hayut and Erez Na’aman, develops next-generation digital microscopes, based on computational imaging breakthroughs, as well as a suite of dedicated image analysis tools. Their products enable dramatic clinical and research improvements in diverse areas such as cancer, hematology and cytology, while powering further innovation in areas such as academic research and drug discovery. The company will use the funds to expand the team based in Tel Aviv, and is hiring computer vision experts, physicists and software developers.
Hayut said, "We look forward to working with OurCrowd’s healthcare team and their thousands of investors. We hope to gain from OurCrowd’s growing network of committed partners around the globe to add significant value to our business and help us pioneer the next generation of digital microscopy applications."
OurCrowd CEO Jon Medved said, "We are excited by our latest investment in Scopio Labs, which is bringing about a revolution in digital microscopy. Scopio Labs joins our portfolio of 23 cutting edge disruptive healthcare technology companies, all of which impact positively the lives of millions of people and are transforming patient care."
This is OurCrowd’s 23rd healthtech investment for a total of $80 million, making OurCrowd the world’s leading equity crowdfunding platform for healthcare investments.
Published by Globes [online], Israel business news - www.globes-online.com - on May 24, 2017
© Copyright of Globes Publisher Itonut (1983) Ltd. 2017